Provenance Manifest

Why this page exists

Wellness Vision produces faceless cost-comparison documentary content using an AI-assisted production stack. Under the European Union AI Act Article 50 (effective 2 August 2026), deployers of generative AI systems must disclose synthetic media to viewers in clear, conspicuous, and accessible form.

This page enumerates every AI-generated or AI-assisted asset that contributed to the video above. It is the canonical provenance reference for editorial transparency, regulatory compliance, and audience trust.

Disclosure stack

• Description footer (YouTube + cross-platform): AI Disclosure block listing all four production tools.
• YouTube Studio toggles: Altered content + Synthetic content (Data API v3 containsSyntheticMedia: true).
• Per-platform manual disclosure: TikTok AI Disclosure per-Short; Instagram Meta AI Content label per-Reel; X thread AI disclosure footer.
• C2PA Content Credentials: DALL-E thumbnail credentials verified with c2patool at the release gate.
• This transparency page: Per-asset IPTC digitalSourceType + SynthID + C2PA status enumerated below.

Honest Caveats

• The video's prices are dated list figures. The ~$936/month US list price and the international figures it cites (~$93 UK, ~$87 Australia, ~$83 France, ~$147 Canada, ~$169 Japan) come from the Peterson-KFF Health System Tracker and are not current. The website's Ozempic page now uses official October 2026 figures for the same 1 mg pen: $995.82 US pharmacy acquisition cost (CMS NADAC), €76.58 in France and £73.25 on the NHS. From January 1, 2027 the US list price falls to $675 and Medicare's negotiated price is $274 for a 30-day supply; Medicare's $50 GLP-1 Bridge copay covers weight-loss drugs, not Ozempic.
• This is a cost comparison only — efficacy and clinical outcomes are out of scope. The video makes no claim about how well any GLP-1 drug works, who should take it, or what dose. It compares prices for the identical brand-name pen across countries. Drug decisions belong with a licensed prescriber.
• "Cheaper abroad" is reported, not recommended. The video does not advise importing, compounding, or buying medication abroad. The FDA says personal importation is illegal in most circumstances, and counterfeit semaglutide has reached the regulated supply chain in the US, UK and Brazil. The cheapest source is often the least verified.
• Most assets lack SynthID watermarks. Grok Imagine, Azure Neural TTS (user-perceivable layer), and Soundraw do not emit SynthID at output. Wellness compensates with explicit human-readable disclosure on every surface (description footer + Studio toggles + per-platform manual + this transparency page).
• Microsoft Speech Watermark is separate from SynthID. Azure Neural TTS embeds a Microsoft-proprietary speech watermark for traceability, but it is not detectable by SynthID-aware badge systems (SYNTHID_GAP_DISCLOSURE_PLAYBOOK §3).
• EU AI Act Article 50 obligations remain with Wellness as deployer. Even where individual tools lack output watermarks, Wellness as the deploying creator bears the disclosure obligation in jurisdictions where viewers access the content.
• No human voice actor was employed. The narration is fully AI-generated. Wellness does not impersonate real persons (Article 50 make-a-real-person-appear-to-say-something clause not triggered).

Editorial Policy

Wellness Vision does not book trips, does not receive clinic referrals, and does not recommend specific providers. We take nothing from any drug company. All cost data derives from the high-trust public sources cited in the video description. This is a cost comparison, not medical advice.

For corrections, additional disclosures, or reproducibility questions related to this video's provenance, contact editorial@wellnessvision.health.

You shouldn't have to go broke to feel whole.